search
Back to results

To Study Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1656 in Japanese Type 2 Diabetes Mellitus (T2DM) Patients (JMAD)

Primary Purpose

Type 2 Diabetes

Status
Completed
Phase
Phase 1
Locations
Japan
Study Type
Interventional
Intervention
AZD1656
Placebo
Sponsored by
AstraZeneca
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes focused on measuring AZD1656, Safety, Pharmacokinetics, Pharmacodynamic, Multiple ascending doses, Japanese, T2DM

Eligibility Criteria

30 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male or female non-childbearing potential Japanese T2DM patients, 30-75 years.
  • A body mass index (BMI) of 19 to 27 kg/m2.
  • Diagnosed Diabetes Mellitus patients treated with diet and exercise or with up to two oral anti-diabetic drugs. Stable glycemic control indicated by no changed treatment within 3 months prior to enrollment.

Exclusion Criteria:

  • Renal dysfunction GFR < 60 mL/min.
  • Systolic pressure (SBP) > 160 mmHg or diastolic pressure (DBP) > 95 mmHg
  • Clinically significant illness or clinically relevant trauma, as judged by the investigator, within two weeks before the first administration of the IP.
  • History of ischemic heart disease, stroke, transient ischemic attack or symptomatic peripheral vascular disease.

Sites / Locations

  • Research Site
  • Research Site

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

A

B

Arm Description

3 gradually increasing repeated oral doses of AZD1656 given to 3 groups (6 on active substance in each group)

Placebo oral suspension given to 3 groups (2 on placebo in each group)

Outcomes

Primary Outcome Measures

Safety by assessment of adverse events, BP, pulse rate, plasma glucose, safety laboratory variables and ECG

Secondary Outcome Measures

Pharmacokinetic variables (AUC, Cmax, tmax, t½, CL/F, Ae and CLR).
Pharmacodynamic variables (P-Glucose, S-Insulin and S-C-peptide).

Full Information

First Posted
June 8, 2009
Last Updated
November 2, 2009
Sponsor
AstraZeneca
search

1. Study Identification

Unique Protocol Identification Number
NCT00916604
Brief Title
To Study Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1656 in Japanese Type 2 Diabetes Mellitus (T2DM) Patients
Acronym
JMAD
Official Title
A Randomized, Single-blind, Placebo-Controlled, Multi-centre, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Multiple Ascending Oral Doses of AZD1656 in Japanese T2DM Patients
Study Type
Interventional

2. Study Status

Record Verification Date
November 2009
Overall Recruitment Status
Completed
Study Start Date
May 2009 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
October 2009 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
AstraZeneca

4. Oversight

5. Study Description

Brief Summary
The purpose of this study is to assess the safety and tolerability of AZD1656 after multiple repeated oral doses in Japanese patients with type 2 diabetes.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes
Keywords
AZD1656, Safety, Pharmacokinetics, Pharmacodynamic, Multiple ascending doses, Japanese, T2DM

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
24 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
A
Arm Type
Experimental
Arm Description
3 gradually increasing repeated oral doses of AZD1656 given to 3 groups (6 on active substance in each group)
Arm Title
B
Arm Type
Placebo Comparator
Arm Description
Placebo oral suspension given to 3 groups (2 on placebo in each group)
Intervention Type
Drug
Intervention Name(s)
AZD1656
Intervention Description
Three increasing dose-steps with oral suspension, 8 days treatment
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo oral suspension, 8 days treatment
Primary Outcome Measure Information:
Title
Safety by assessment of adverse events, BP, pulse rate, plasma glucose, safety laboratory variables and ECG
Time Frame
Blood samples taken repeatedly during 24 hours on study day sessions
Secondary Outcome Measure Information:
Title
Pharmacokinetic variables (AUC, Cmax, tmax, t½, CL/F, Ae and CLR).
Time Frame
Blood samples taken repeatedly during 24 hours on study day sessions
Title
Pharmacodynamic variables (P-Glucose, S-Insulin and S-C-peptide).
Time Frame
Blood samples taken repeatedly during 24 hours on study day sessions

10. Eligibility

Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female non-childbearing potential Japanese T2DM patients, 30-75 years. A body mass index (BMI) of 19 to 27 kg/m2. Diagnosed Diabetes Mellitus patients treated with diet and exercise or with up to two oral anti-diabetic drugs. Stable glycemic control indicated by no changed treatment within 3 months prior to enrollment. Exclusion Criteria: Renal dysfunction GFR < 60 mL/min. Systolic pressure (SBP) > 160 mmHg or diastolic pressure (DBP) > 95 mmHg Clinically significant illness or clinically relevant trauma, as judged by the investigator, within two weeks before the first administration of the IP. History of ischemic heart disease, stroke, transient ischemic attack or symptomatic peripheral vascular disease.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Klas Malmberg, MD
Organizational Affiliation
AstraZeneca R&D Mölndal
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Takashi Eto, MD, PhD
Organizational Affiliation
PS Clinic, Fukuoka, Japan
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Mitsuyasu Hokamura, MD
Organizational Affiliation
HONJO CLINIC II, Tokyo, Japan
Official's Role
Principal Investigator
Facility Information:
Facility Name
Research Site
City
Fukuoka
Country
Japan
Facility Name
Research Site
City
Tokyo
Country
Japan

12. IPD Sharing Statement

Learn more about this trial

To Study Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1656 in Japanese Type 2 Diabetes Mellitus (T2DM) Patients

We'll reach out to this number within 24 hrs